In this work, the characterisation and the optimisation of hybridisation assays based on a novel, rapid and sensitive micro-analytical, gravity-driven, flow device is reported. This device combines a special chip containing eight polymer microchannels, with a portable, computer-controlled instrument. The device is used as a platform for affinity experiments using oligonucleotide-modified paramagnetic particles. In our approach, both hybridisation and labelling events are performed on streptavidin-coated paramagnetic microparticles functionalized with a biotinylated capture probe. Modified particles, introduced in the microchannel inlet of the chip, accumulate near the electrode surface by virtue of a magnetic holder. After hybridisation with the complementary sequence, the hybrid is labelled with an alkaline phosphatase conjugate. The electrochemical substrate for alkaline phosphatase revelation is p-aminophenyl phosphate. Solutions and reagents are sequentially passed through the microchannels, until enzyme substrate is added for in situ signal detection. Upon readout, the magnet array is flipped away, beads are removed by addition of regeneration buffer, and the so-regenerated chip is ready for further analysis. This protocol has been applied to the analytical detection of specific DNA sequences of Legionella pneumophila, with an RSD=8.5% and a detection limit of 0.33 nM.

Download full-text PDF

Source
http://dx.doi.org/10.1002/elps.201000288DOI Listing

Publication Analysis

Top Keywords

alkaline phosphatase
8
gravity-driven microfluidic-based
4
microfluidic-based electrochemical
4
electrochemical assay
4
assay coupled
4
coupled magnetic
4
magnetic beads
4
beads nucleic
4
nucleic acid
4
detection
4

Similar Publications

Biomarkers.

Alzheimers Dement

December 2024

Beckman Coulter Inc., Chaska, MN, USA.

Background: The analytical performance characteristics for the plasma Glial Fibrillary Acidic Protein (GFAP) immunoassay currently under development on Beckman Coulter, Inc. Access2™ and DxI9000™ analyzers is described. Blood GFAP levels may be indicative of the extent of neurologic injury in diseases such as TBI and stroke and maybe used as a marker of disease progression in other diseases such as multiple sclerosis.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Beckman Coulter Inc., Chaska, MN, USA.

Background: Hyperphosphorylated Tau is a pathologic hallmark of the neurofibrillary tangles in Alzheimer's Disease (AD). p-Tau is a promising blood-based biomarker in AD research, drug development, diagnosis, disease monitoring, and patient care. Several assays for p-Tau in plasma have been previously described, however there is a need to make this test easily available to the clinical laboratories around the world and more accessible to the patients and the clinicians.

View Article and Find Full Text PDF

Background: Alzheimer's disease (AD) is a neurodegenerative disorder characterised by cognitive decline and progressive deterioration of brain function. Recent research has suggested a complex interplay between AD and bone health, with individuals affected by AD exhibiting an increased propensity for fractures and falls. Our preclinical studies in PSEN, MAPT P301 S and FDD mice have shown sex-dependent changes in the bone in AD mice, compared to their age-matched wild type mice.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

ADx NeuroSciences NV, Ghent, Belgium.

Background: Among the different phospho-tau sites, phosphorylation at Threonine 205 (pTau205) in CSF has been shown to be closely associated with Tau-PET (Lantero-Rodriguez et al. 2024; Barthélemy et al. 2023).

View Article and Find Full Text PDF

Purpose Of Review: This review explores the emerging concept of "deep response" in primary biliary cholangitis (PBC), defined by the normalization of biochemical markers, particularly alkaline phosphatase and bilirubin. It examines its potential as a new standard for disease management and its implications for long-term patient outcomes, health policies, and clinical decision-making.

Recent Findings: Recent studies suggest that achieving a deep response significantly improves long-term outcomes in some patients with PBC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!